The Quest for Off-the-Shelf CAR T Cells.
Various companies are exploring ways to manufacture allogeneic chimeric antigen receptor T cells, which could then be administered off the shelf to multiple recipients, thereby expanding access to this immunotherapy. However, challenges, such as finding ways to address the twin complications of graft-versus-host disease and host rejection of the therapeutic product, remain.